Four leading drugmakers were back in federal court on Thursday to challenge the constitutionality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.

Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson presented their arguments to Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey. This hearing was different from the others in that the court allowed the four companies to present their oral arguments in a single session.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee-Paid
Employer-Paid